Mitsui and Oncoshot Forge Asia US Clinical Data Collaboration

Mitsui & Co. has officially entered a strategic service agreement with Oncoshot Pte. Ltd. to deploy proprietary artificial intelligence for clinical data analysis. As detailed in a recent Business Insider report, this partnership aims to build a robust Asia-US clinical data network. The initiative heavily relies on real-world data from oncology specialists within the IHH Healthcare Berhad network, alongside other prominent medical institutions across the Asia-Pacific region.

The global demand for high-quality clinical data is surging across drug discovery and trial design. However, a major bottleneck persists in modern medical research. Valuable patient information remains trapped in fragmented, unstructured formats within individual hospital systems. Strict privacy regulations and institution-specific governance rules often make cross-border data transfer nearly impossible. This leaves researchers with limited access to diverse Asian patient populations, slowing down the development of globally representative medical evidence and personalized therapies.

Oncoshot addresses this exact pain point with a novel approach. The company has engineered an AI-powered system that efficiently anonymizes and structures electronic medical records and lab results directly inside the healthcare institution. By converting this raw information into research-ready datasets without ever moving the data outside its original secure environment, the technology respects stringent privacy constraints while unlocking its scientific value for pharmaceutical developers.

This collaboration is deeply integrated with top-tier global research bodies. Oncoshot is an active participant in the MSK iHub, a business accelerator program run by Memorial Sloan Kettering Cancer Center. Neil J. Shah, an Assistant Attending Physician at MSK, emphasized that cancer is a global disease requiring a deeper understanding of treatment outcomes across varied healthcare systems and demographics.

To achieve this harmonization, MSK provides a standardized pan-cancer data model known as the Common Cancer Data Elements framework. This ontology-driven approach allows the new partnership to align oncology outcomes data seamlessly across different countries, accelerating international collaborative research and shortening study timelines.

Industry data underscores the massive scale of this opportunity. The Asia-Pacific clinical trials market was valued at approximately $18.87 billion in 2025, according to Towards Healthcare. Furthermore, the global clinical data management market sits at around $3.62 billion, as noted by Precedence Research. With AI in APAC clinical trials projected to hit $1.61 billion by 2026 per Roots Analysis, the timing for this collaboration is ideal. This is especially true given that the IHH Healthcare network already spans 89 hospitals across 10 countries, providing a massive foundational dataset.

This initiative aligns perfectly with Mitsui’s Medium-term Management Plan 2029, which highlights "Wellness Ecosystem Creation 2.0" as a core strategic pillar. By leveraging IHH’s massive regional footprint and Oncoshot’s localized AI processing, the partnership promises to remove historical friction from clinical data sharing. Ultimately, this cross-continental bridge will help pharmaceutical innovators generate stronger, more diverse evidence, paving the way for more effective cancer treatments worldwide.